Do analysts prefer CUE or LITS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate LITS or KLRS?

Kalaris Therapeutics has a consensus price target of $15.60, indicating a potential upside of 253.34%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Is LITS or KLRS more profitable?

Kalaris Therapeutics' return on equity of -72.78% beat Lite Strategy's return on equity. Company Net Margins Return on Equity Return on Assets Lite Strategy N/A -90.81% -89.33% Kalaris Therapeutics N/A -72.78% -43.49%

Does the media refer more to LITS or KLRS?

In the previous week, Lite Strategy had 3 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 4 mentions for Lite Strategy and 1 mentions for Kalaris Therapeutics. Lite Strategy's average media sentiment score of 0.50 beat Kalaris Therapeutics' score of 0.00 indicating that Lite Strategy is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lite Strategy 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer LITS or PYXS?

Pyxis Oncology has a consensus price target of $6.83, suggesting a potential upside of 220.06%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Is LITS or PYXS more profitable?

Lite Strategy's return on equity of -90.81% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Lite Strategy N/A -90.81% -89.33% Pyxis Oncology N/A -135.60% -85.00%

Does the media favor LITS or PYXS?

In the previous week, Lite Strategy had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Lite Strategy and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.76 beat Lite Strategy's score of 0.50 indicating that Pyxis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lite Strategy 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pyxis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIFC or LITS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, AIFC or LITS?

Lite Strategy has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.74 -$344.51M N/A N/A Lite Strategy $65.30M 0.46 -$15.94M -$1.60 N/A

Is AIFC or LITS more profitable?

Lite Strategy has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Lite Strategy's return on equity. Company Net Margins Return on Equity Return on Assets ALT5 Sigma -2,483.94% -68.25% -62.43% Lite Strategy N/A -90.81% -89.33%

Do analysts recommend LITS or ALDX?

Aldeyra Therapeutics has a consensus target price of $5.50, indicating a potential upside of 167.64%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is LITS or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Lite Strategy's return on equity. Company Net Margins Return on Equity Return on Assets Lite Strategy N/A -90.81% -89.33% Aldeyra Therapeutics N/A -57.34% -36.33%

Does the media refer more to LITS or ALDX?

In the previous week, Lite Strategy had 3 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Lite Strategy and 1 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.75 beat Lite Strategy's score of 0.50 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lite Strategy 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aldeyra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lite Strategy (LITS) Competitors

$0.89 +0.06 (+7.39%)

As of 03:57 PM Eastern

Compare

LITS vs. CUE, KLRS, PYXS, AIFC, and ALDX

Should you buy Lite Strategy stock or one of its competitors? MarketBeat compares Lite Strategy with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lite Strategy include Cue Biopharma (CUE), Kalaris Therapeutics (KLRS), Pyxis Oncology (PYXS), ALT5 Sigma (AIFC), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical products" industry.

How does Lite Strategy compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 52.4% of Lite Strategy shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by insiders. Comparatively, 1.6% of Lite Strategy shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cue Biopharma has a beta of 2.51, meaning that its stock price is 151% more volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

In the previous week, Lite Strategy had 4 more articles in the media than Cue Biopharma. MarketBeat recorded 4 mentions for Lite Strategy and 0 mentions for Cue Biopharma. Lite Strategy's average media sentiment score of 0.50 beat Cue Biopharma's score of 0.00 indicating that Lite Strategy is being referred to more favorably in the news media.

Company	Overall Sentiment
Cue Biopharma	Neutral
Lite Strategy	Neutral

Lite Strategy has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Lite Strategy's return on equity of -90.81% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Lite Strategy	N/A	-90.81%	-89.33%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lite Strategy has higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.76	-$26.60M	-$5.58	N/A
Lite Strategy	$65.30M	0.46	-$15.94M	-$1.60	N/A

Summary

Lite Strategy beats Cue Biopharma on 9 of the 13 factors compared between the two stocks.

How does Lite Strategy compare to Kalaris Therapeutics?

Lite Strategy (NASDAQ:LITS) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Lite Strategy has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.15, indicating that its share price is 85% less volatile than the broader market.

Kalaris Therapeutics has a consensus price target of $15.60, indicating a potential upside of 253.34%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

52.4% of Lite Strategy shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 1.6% of Lite Strategy shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lite Strategy had 3 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 4 mentions for Lite Strategy and 1 mentions for Kalaris Therapeutics. Lite Strategy's average media sentiment score of 0.50 beat Kalaris Therapeutics' score of 0.00 indicating that Lite Strategy is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lite Strategy	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lite Strategy has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.46	-$15.94M	-$1.60	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Kalaris Therapeutics' return on equity of -72.78% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-90.81%	-89.33%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

Summary

Kalaris Therapeutics beats Lite Strategy on 8 of the 15 factors compared between the two stocks.

How does Lite Strategy compare to Pyxis Oncology?

Lite Strategy (NASDAQ:LITS) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Lite Strategy has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.46	-$15.94M	-$1.60	N/A
Pyxis Oncology	$13.86M	9.76	-$79.62M	-$1.31	N/A

Lite Strategy has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

Pyxis Oncology has a consensus price target of $6.83, suggesting a potential upside of 220.06%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Lite Strategy had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Lite Strategy and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.76 beat Lite Strategy's score of 0.50 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lite Strategy	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pyxis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lite Strategy's return on equity of -90.81% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-90.81%	-89.33%
Pyxis Oncology	N/A	-135.60%	-85.00%

52.4% of Lite Strategy shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 1.6% of Lite Strategy shares are owned by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Pyxis Oncology beats Lite Strategy on 9 of the 15 factors compared between the two stocks.

How does Lite Strategy compare to ALT5 Sigma?

ALT5 Sigma (NASDAQ:AIFC) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Lite Strategy has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.74	-$344.51M	N/A	N/A
Lite Strategy	$65.30M	0.46	-$15.94M	-$1.60	N/A

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 52.4% of Lite Strategy shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by company insiders. Comparatively, 1.6% of Lite Strategy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Lite Strategy had 4 more articles in the media than ALT5 Sigma. MarketBeat recorded 4 mentions for Lite Strategy and 0 mentions for ALT5 Sigma. Lite Strategy's average media sentiment score of 0.50 beat ALT5 Sigma's score of 0.00 indicating that Lite Strategy is being referred to more favorably in the news media.

Company	Overall Sentiment
ALT5 Sigma	Neutral
Lite Strategy	Neutral

ALT5 Sigma has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

Lite Strategy has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Lite Strategy	N/A	-90.81%	-89.33%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Lite Strategy beats ALT5 Sigma on 7 of the 11 factors compared between the two stocks.

How does Lite Strategy compare to Aldeyra Therapeutics?

Lite Strategy (NASDAQ:LITS) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Lite Strategy has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

Aldeyra Therapeutics' return on equity of -57.34% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-90.81%	-89.33%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

52.4% of Lite Strategy shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 1.6% of Lite Strategy shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lite Strategy has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.46	-$15.94M	-$1.60	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Aldeyra Therapeutics has a consensus target price of $5.50, indicating a potential upside of 167.64%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Lite Strategy had 3 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Lite Strategy and 1 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.75 beat Lite Strategy's score of 0.50 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lite Strategy	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aldeyra Therapeutics beats Lite Strategy on 10 of the 14 factors compared between the two stocks.

Get Lite Strategy News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LITS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LITS vs. The Competition

Export

Metric	Lite Strategy	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$30.22M	$935.12M	$4.41B	$12.38B
Dividend Yield	N/A	4.84%	10.94%	5.81%
P/E Ratio	-0.56	1.44	22.12	24.28
Price / Sales	0.46	121.45	166.99	129.97
Price / Cash	0.14	20.06	41.09	37.84
Price / Book	0.18	7.72	18.37	6.58
Net Income	-$15.94M	-$5.20M	$115.37M	$336.86M
7 Day Performance	11.06%	0.21%	-0.48%	-0.37%
1 Month Performance	-16.92%	1.57%	-0.92%	1.61%
1 Year Performance	N/A	50.84%	14.49%	33.88%

Lite Strategy Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LITS Lite Strategy	0.8168 of 5 stars	$0.89 +7.4%	N/A	N/A	$30.22M	$65.30M	N/A	100
CUE Cue Biopharma	0.0859 of 5 stars	$25.84 +5.3%	N/A	-95.5%	$109.12M	$27.47M	N/A	60	Gap Down
KLRS Kalaris Therapeutics	3.6198 of 5 stars	$4.58 +5.7%	$15.60 +241.0%	+96.7%	$108.84M	N/A	N/A	110
PYXS Pyxis Oncology	3.5318 of 5 stars	$1.71 -3.1%	$6.83 +300.8%	+73.5%	$108.02M	$13.86M	N/A	60	Positive News
AIFC ALT5 Sigma	0.0782 of 5 stars	$0.77 +15.8%	N/A	-92.9%	$107.68M	$24.84M	N/A	170	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LITS) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lite Strategy (LITS) Competitors

LITS vs. CUE, KLRS, PYXS, AIFC, and ALDX

How does Lite Strategy compare to Cue Biopharma?

Summary

How does Lite Strategy compare to Kalaris Therapeutics?

Summary

How does Lite Strategy compare to Pyxis Oncology?

Summary

How does Lite Strategy compare to ALT5 Sigma?

Summary

How does Lite Strategy compare to Aldeyra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LITS vs. The Competition

Lite Strategy Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lite Strategy (LITS) Competitors

LITS vs. CUE, KLRS, PYXS, AIFC, and ALDX

How does Lite Strategy compare to Cue Biopharma?

Do institutionals & insiders believe in CUE or LITS?

Which has more volatility and risk, CUE or LITS?

Does the media prefer CUE or LITS?

Is CUE or LITS more profitable?

Do analysts prefer CUE or LITS?

Which has preferable valuation and earnings, CUE or LITS?

Summary

How does Lite Strategy compare to Kalaris Therapeutics?

Which has more risk and volatility, LITS or KLRS?

Do analysts rate LITS or KLRS?

Do institutionals and insiders believe in LITS or KLRS?

Does the media refer more to LITS or KLRS?

Which has preferable earnings and valuation, LITS or KLRS?

Is LITS or KLRS more profitable?

Summary

How does Lite Strategy compare to Pyxis Oncology?

Which has preferable earnings and valuation, LITS or PYXS?

Which has more volatility & risk, LITS or PYXS?

Do analysts prefer LITS or PYXS?

Does the media favor LITS or PYXS?

Is LITS or PYXS more profitable?

Do insiders and institutionals have more ownership in LITS or PYXS?

Summary

How does Lite Strategy compare to ALT5 Sigma?

Which has better earnings & valuation, AIFC or LITS?

Do insiders & institutionals believe in AIFC or LITS?

Does the media prefer AIFC or LITS?

Which has more volatility & risk, AIFC or LITS?

Is AIFC or LITS more profitable?

Do analysts recommend AIFC or LITS?

Summary

How does Lite Strategy compare to Aldeyra Therapeutics?

Which has more volatility & risk, LITS or ALDX?

Is LITS or ALDX more profitable?

Do institutionals and insiders believe in LITS or ALDX?

Which has higher earnings & valuation, LITS or ALDX?

Do analysts recommend LITS or ALDX?

Does the media refer more to LITS or ALDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LITS vs. The Competition

Lite Strategy Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools